TNXP - Tonix announces partnership to study monkeypox vaccine in 1H 2023

• Clinical-stage biotech Tonix Pharmaceuticals ( NASDAQ: TNXP ) announced a partnership with the Kenya Medical Research Institute on Thursday to design and conduct a Phase 1 clinical trial in the African country for TNX-801, a vaccine targeted at monkeypox and smallpox.
• Chief Executive of Tonix ( TNXP ) Seth Lederman noted that TNX-801 is a live virus vaccine, and those who received live virus vaccines for smallpox before eradication appeared to sustain protection against the related monkeypox virus.
• The design of TNX-801 more closely resembles the smallpox vaccines used in the U.S. and Europe before 1900 than the vaccinia smallpox vaccines, which include the ACAM2000 vaccine developed by Emergent BioSolutions ( EBS ) for smallpox.
• “TNX-801 has reduced virulence in animals, and we believe it has the potential for widespread use to protect against monkeypox,” Lederman added.
• Last week, the World Health Organization declared monkeypox a public health emergency of international concern (PHEIC), sending the makers of therapeutics and vaccines for the rare viral disease sharply higher on Monday.

For further details see: